Drugstore, pharma firm ordered to stop immunization offer | Inquirer News

Drugstore, pharma firm ordered to stop immunization offer

/ 02:22 PM May 06, 2017

The Food and Drug Administration has ordered a pharmaceutical company and a drug store chain to cease and desist from promoting and conducting immunization activities in its stores.

Sanofi Pasteur, Inc. and Watson’s Personal Care Stores were told to explain why administrative and criminal cases should not be filed against them for conducting such activities without authorization.

In a statement, FDA director general Nela Charade Puno said the agency did not issue any authorization to allow immunization services to be conducted by Sanofi, Watson’s or any drug store.

Article continues after this advertisement

“There is no assurance on the safety and quality of the service rendered in these drugstores and thus poses a potential health hazard to the consuming public,” Puno said.

FEATURED STORIES

The cease and desist order was issued following Watson’s announcement that it will conduct immunization activities using the dengue vaccine created by Sanofi, Dengvaxia.

A dose of the vaccine costs P 4,000 at the drug store, with three doses to be administered in a year.

Article continues after this advertisement

In April, the FDA’s Center for Drug Regulation and Research monitored the unauthorized advertisement and promotion of the said vaccine by Watson’s.

Article continues after this advertisement

The agency noted that the drug store chain misrepresented Dengvaxia as available over the counter despite its classification as a prescription drug approved only for those nine to 45 years old.

Article continues after this advertisement

The FDA said it will ask Sanofi to explain why they violated the law for the second time.

It may be recalled that in December last year, the agency issued a cease and desist order and also filed a case against the pharmaceutical firm for the unauthorized promotion of Dengvaxia.

Article continues after this advertisement

Puno warned that if the FDA is not satisfied with Sanofi’s explanation or if the firm continues to commit violations, they will suspend or cancel the vaccine’s certificate of product registration.
“Laws are mandatory and they are meant to be followed. Compliance to the law is not optional, especially when the safety and health of the public are involved,” the FDA chief said.

Puno added: “Sanofi, Watson’s and other manufacturers and drug stores are hereby warned. Nobody is exempt.”

Aside from advising the public not to avail the unauthorized immunization activities in Watson’s branches, the FDA also directed drug stores from conducting immunization activities until the appropriate regulation and appropriate authorization have been issued.

“Regulation action and sanctions shall be strictly pursued in case of non- compliance,” Puno said.
If a drugstore wants to undertake additional services such as vaccination activities, it must apply for variation of its license to operate the FDA.

Among the FDA’s requirement for drugstore-initiated immunizations are: patient counselling, qualification of the person administering the vaccine, dedicated space and sanitation.

Meanwhile the FDA and Department of Health will train and authorize FDA-licensed community pharmacists to administer adult vaccines and other immunization products.

The FDA urged the public to report unauthorized immunizations in drug stores through email, [email protected], or at the FDA’s online reporting facility at www.fda.gov.ph.

RELATED STORIES

Dengue vaccination program: Should it be continued?

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

A second thought on the dengue vaccine

TAGS: Dengvaxia, FDA, immunization, Sanofi, Watsons

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.